Genetic Technologies Regains Nasdaq Listing Compliance
January 09 2018 - 5:00AM
Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”),
is pleased to advise that the Company received a notification
letter (the "Notice") from the Listing Qualifications Department of
The Nasdaq Stock Market on January 8, 2018 notifying the Company
that the minimum closing bid price per share was $US1.00 or above
for a period of 10 consecutive business days from December 20, 2017
to January 4, 2018, and as a result the Company has regained
compliance with Nasdaq Marketplace Listing Rule 5550(a)(2).
The Notice confirms that the Nasdaq Listing
Rules deficiency notice of July 19, 2017, has been remedied and
that the matter is now closed.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli
Executive Director & Chief Executive
Officer
Genetic
Technologies Limited
+ 61 3 8412
7050
Jason Wong (USA) Blueprint Life Science Group +
1 (415) 375 3340, Ext. 4
About Genetic Technologies
LimitedGenetic Technologies is a molecular diagnostics
company that offers cancer predictive testing and assessment tools
to help physicians proactively manage patient health. The Company’s
lead product, BREVAGenplus®, is a clinically validated risk
assessment test for non-hereditary breast cancer and is first in
its class. BREVAGenplus is designed to facilitate better
informed decisions about breast cancer screening and preventive
treatment plans, and is directed towards women aged 35 years or
above, who have not had breast cancer and have one or more risk
factors for developing breast cancer.
The Company markets BREVAGenplus, through its
U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals
in comprehensive breast health care and imaging centres, as well as
to obstetricians/gynaecologists (OBGYNs) and breast cancer risk
assessment specialists (such as breast surgeons). For more
information, please visit www.brevagenplus.com and
www.phenogensciences.com.
Genetic Technologies is developing a pipeline of
risk assessment products including a novel colorectal cancer (CRC)
test. For more information, please visit www.gtgcorporate.com
Safe Harbor StatementAny
statements in this press release that relate to the Company's
expectations are forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act. The Private
Securities Litigation Reform Act of 1995 (PSLRA) implemented
several significant substantive changes affecting certain cases
brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2024 to May 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From May 2023 to May 2024